Schlanger David J 4
4 · Progyny, Inc. · Filed Mar 27, 2024
Insider Transaction Report
Form 4
Progyny, Inc.PGNY
Schlanger David J
DirectorExecutive Chairman
Transactions
- Sale
Common Stock
2024-03-26$37.50/sh−305$11,439→ 86,312 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-03-26−305→ 1,381,294 totalExercise: $3.95Exp: 2029-05-23→ Common Stock (305 underlying) - Sale
Common Stock
2024-03-25$37.65/sh−2,597$97,778→ 86,312 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-03-25−2,597→ 1,381,599 totalExercise: $3.95Exp: 2029-05-23→ Common Stock (2,597 underlying) - Exercise/Conversion
Common Stock
2024-03-25$3.95/sh+2,597$10,270→ 88,909 total - Exercise/Conversion
Common Stock
2024-03-26$3.95/sh+305$1,206→ 86,617 total
Footnotes (4)
- [F1]Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 23, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.55 to $37.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $37.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]These options are fully vested and exercisable.